Management is buying the same thing twice: proven demand from one place is being replicated into identified new places r
The model's full reasoning — Q1 2017 call → NOWe need to determine if the transcript describes a situation where the company is currently in the middle of copying a part of its own business that is already working into additional places where the same demand is already visible. The key elements: (1) a proven instance that works, (2) copies being stood up now, (3) demand already identified at the destination. Let's analyze the transcript. The company is Ionis Pharmaceuticals. They have SPINRAZA, a drug for SMA, which is launched and generating sales. They have volanesorsen for FCS, which is in Phase III and they are preparing to launch. They have IONIS-TTRRx, etc. The question is about "copying a part of its own business" - meaning replicating a proven business model or unit. For example, if they have a successful commercial infrastructure for one drug and are replicating it for another drug. Or if they have a successful sales force and are expanding it to new markets. Let's look for such a description. The transcript mentions Akcea, a subsidiary, which is building a commercial team to launch volanesorsen. They are also planning an IPO for Akcea. But is that a copy of a proven instance? Akcea is building a sales force for volanesorsen, but volanesorsen is not yet approved or launched. So that is not a proven instance. What about SPINRAZA? They have a commercial launch with Biogen. They are expanding to EU, Canada, Japan. But that is not copying a business unit; it's expanding the market for the same drug. The question is about copying a part of the business that already works into additional places. For example, if they have a successful sales force in the US and are replicating it in Europe. But here, Biogen is handling SPINRAZA globally. So Ionis is not standing up copies of its own sales force. Maybe the question is about the technology platform? They have a platform for antisense drugs. They are creating new drugs. But that is not a business unit being copied. Let's read carefully. The transcript mentions "we're now able to retain a larger portion of the commercial value from our drugs in a number of ways, including develop our -- developing our drugs longer before partnering and creating subsidiaries like Akcea to develop and commercialize additional drugs in our pipeline." That is about creating a subsidiary, not copying a proven instance.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| VSEC | VSE Corporation | Q3 2022 | 2022-10-28 | B+ |
| FSLR | First Solar, Inc. | Q3 2022 | 2022-10-28 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| TPIC | TPI Composites, Inc. | Q3 2018 | 2018-11-11 | C |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOLD | Amicus Therapeutics, Inc. | Q1 2018 | 2018-05-08 | C+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| VSAT | Viasat, Inc. | Q4 2017 | 2017-05-23 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GDS · Q2 2021 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a clear, present-tense replication of their proven China-based data center platform into new markets (Hong Kong, Macau, Southeast Asia) where demand is already visible and committed. William Huang explicitly references the “proven” China edge-of-town model (land-and-expand MOUs, 500 000 sqm secured pipeline, hyperscale orders already landed) and states they are “currently developing two purpose-built data centers” in Hong Kong (HK1/HK2) with most capacity “already allocated to strategic customers pending contracts,” plus a new building (HK4) under agreement and a heads-of-agreement for HK3, creating “nearly 80 megawatts of purpose-built capacity through to 2027.” For Macau they have a JV to acquire brownfield sites for redevelopment (20 MW).
FOLD · Q1 2018 → YESThe question is about whether management describes the company as currently copying a proven part of its business into additional places where demand is already visible. YES The transcript shows management describing Galafold as a proven commercial offering (Q1 revenue $16.7M, 300% YoY growth, hundreds of patients, high compliance, 7 approvals, 18 countries with pricing/reimbursement) that is now being replicated into additional markets.
TPIC · Q3 2018 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a proven manufacturing operation (existing dedicated lines and plants in the U.S.